Another trial, assessing early-18F-FDG-PET/CT response in breast cancer patients treated with double HER2-blockade (trastuzumab and lapatinib) in the neoadjuvant setting, selected as a threshold a 15% reduction of the SUVmax in all target lesions to define response12. This evidence concerns the gene ERBB2 and breast cancer.